Tag: Drug-eluting technology

Potential ‘new paradigm’ in treatment of long occlusive lesions emerges

Vascular surgeon Lewis Schwartz, MD, has had an interest in biomedical engineering since very early in his career. So his involvement in the early-stage...

VAM discussion on latest paclitaxel meta-analysis yields mix of caution, skepticism

A Vascular Annual Meeting (VAM) sponsored session on paclitaxel safety drew a mix of skeptical and cautious responses to the latest meta-analysis from interventional...

PRISTINE registry with Selution SLR sirolimus drug-eluting balloon completes enrollment

MedAlliance has announced completion of patient enrollment in the PRISTINE clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of patients with below-the-knee...

Postmarket study of sirolimus-eluting balloon enrolls first patient

MedAlliance has announced enrollment of the first patient in SUCCESS PTA, its large post-market study with the drug-eluting balloon Selution SLR for the treatment...

Veterans study: No evidence of increased risk of death with use...

A study of more than 10,000 U.S. veterans with peripheral arterial disease (PAD) undergoing endovascular interventions in the femoropopliteal segment found that rates of...

MHRA: Warning to be added to paclitaxel device IFUs in Europe

In a new field safety notice, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) states that a warning and clinical summary section will be...
Richard Neville

Drug-coated technology question aired during SAVS opening session

PALM BEACH, Fla.—Discussion of the drug-coated technology issue was piqued during the opening session of the Southern Association for Vascular Surgery (SAVS) annual meeting...